États-Unis · Plateformes & données · TipRanks

Cantargia Reports Early Nadunolimab Responses in MDS and AML

Publié par TipRanks · États-Unis il y a 8 h

Nadunolimab combinations produced responses in MDS and AML. Limited treatment-related severe toxicity supported nadunolimab’s early profile. Looking for the best stocks to buy?…

Lire l'article complet sur TipRanks Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.tipranks.com)

Cantargia Reports Early Nadunolimab Responses in MDS and AML

À lire aussi

Oportun Financial (NASDAQ:OPRT) Sets New 12-Month High After Better-Than-Expected Earnings

Big Tech’s $500 billion spending spree leaves a lot less for shareholders

ConocoPhillips Q3 preview: High expectations as upstream focus drives growth

2 Berkshire Hathaway Holdings to Buy After Record Third Quarters

Democrats win control of Congress as voters rebuke Trump agenda

Treasury yields fall after Democrats win House and Senate majorities

Cantargia Reports Early Nadunolimab Responses in MDS and AML

Partager

À lire aussi

Oportun Financial (NASDAQ:OPRT) Sets New 12-Month High After Better-Than-Expected Earnings

Big Tech’s $500 billion spending spree leaves a lot less for shareholders

ConocoPhillips Q3 preview: High expectations as upstream focus drives growth

2 Berkshire Hathaway Holdings to Buy After Record Third Quarters

Democrats win control of Congress as voters rebuke Trump agenda

Treasury yields fall after Democrats win House and Senate majorities